We are developing innovative prognostic tools that permit identifying individuals with an increased risk of multiple infections (hypersusceptibility) prior to infections occurrence. A test able to predict the risk of developing multiple infections would offer prophylaxis to those at risk, allowing clinicians to consider immediate prophylactic interventions other than antibiotics, while to those at low risk spare any potential side effects, such as killing the beneficial microbiota as a result of broad-spectrum antibiotics usage. Widespread antibiotic use contributes to the emergence of MDR pathogens.  

Our key innovation lies in the novel patient prognostic stratification approach and tools that use the expression profiles of multiple genes or proteins to aid in successfully delivering appropriate personalized preventative and therapeutic treatment to patients who are at high risk for infection.   As such, this methodology will permit individualized treatments,  limit the use of antibiotics, promote antibiotic stewardship, streamline appropriate hospital care, reduce healthcare costs, and thereby improve treatment outcomes. One of our ultimate goals is host-targeted immunopotentiation and therapy that will promote the patient’s natural local and systemic defensive responses to restore robust host responses for clearing or preventing infections.  Our approach fundamentally differs from the existing standard of care that focuses on early diagnosis and treatment after infections’ occurrence.